 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Atara Biotherapeutics, Inc. Nasdaq: ATRA; the Company, a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced President and Chief Executive Officer Pascal Touchon will present Ataras 2020 progress and key upcoming milestones across the Companys strategic prior 